|
|
Article: NEOPHARM Provides Update on Reimbursement Progress for CINTREDEKIN BESUDOTOX; Unique Coding Provided for Convection Enhanced Delivery.
- Article from:
- Business Wire
- Article date:
- August 7, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WAUKEGAN, Ill. -- NEOPHARM, Inc. (Nasdaq:NEOL) today announced progress in the Company's reimbursement position for CINTREDEKIN BESUDOTOX (IL13-PE38QQR), which is being studied for the treatment of glioblastoma multiforme at first recurrence, the most common type of malignant primary brain tumor in adults. The American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) have assigned unique CPT and ICD-9 procedure codes, respectively, for Convection Enhanced Delivery (CED) catheter implantation, a novel drug delivery technique used to administer CINTREDEKIN BESUDOTOX directly into the brain. The CPT and ICD-9 procedure coding systems are ...